Havasu, CD12 is an adaptive trial. From tria
Post# of 148185
(Total Views: 753)
Posted On: 10/25/2020 6:38:14 PM
Havasu,
CD12 is an adaptive trial.
From trial registry on clinicatrials.gov
"Detailed Description:
This is a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.
The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period."
CD12 is an adaptive trial.
From trial registry on clinicatrials.gov
"Detailed Description:
This is a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.
The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period."
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼